MAM
Grey ups Subbaraju Alluri as CEO of Singapore & Thailand
MUMBAI: Grey Group Singapore has promoted Subbaraju Alluri to area director and CEO of Grey Group Singapore and Thailand.
Alluri began his career in advertising as a management trainee in DDB Chennai. After stints at JWT and Rapp Collins, he joined Grey Group Indonesia. During his tenure, Alluri was instrumental in expanding the workforce and clinching big accounts like BMW, Indosat, Daihatsu and Wyeth.
His leadership qualities and stellar performance prompted a move to head Grey Group Singapore’s local operations in 2005. He has been credited with boosting the agency’s profitability by leading the team to win major accounts such as Sentosa, Ministry of Manpower, Contact Singapore, LASALLE College of the Arts, GlaxoSmithKline, Norton, Vitagen, Wyeth, British Council, Al-Maha Airways (Regional) and Qatar Airways (global). He also made several strategic senior hires and increased the local team size by five times.
“Raju’s aptitude and contribution has been invaluable. I am sure with his leadership and vision, he will transform Grey Group Thailand into becoming the agency of choice,” Grey Group Asia Pacific chairman & CEO Nirvik Singh.
“It is truly an honour to be given the opportunity to lead the Thailand team, as well. I am looking forward to taking the agency to new and greater heights,” said Alluri.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
